Xiao, F. , Xiao, W. , Li, X., Li, R. and Zhao, K. 2024. Cost-effectiveness analysis of Trastuzumab Deruxtecan as second-line treatment for HER2- positive advanced breast cancer. Health Decision. 2, S1 (Jul. 2024). DOI:https://doi.org/10.54844/hd.2024.0009.